EXPERT EVALUATION OF PRECLINICAL STUDIES OF PRIMARY AND SECONDARY PHARMACODYNAMICS OF MEDICINES

The article dwells upon the results of comparative analysis of the Russian national requirements  and EAEU regulations dealing with evaluation of preclinical pharmacological studies. It highlights historical aspects of elaboration of regulatory requirements and scientific and methodological  recommendations for conducting  and evaluating preclinical pharmacological  studies. According to the EAEU Rules of registration and evaluation of medicinal products for human use, the Common  Technical Document has to include information  on primary pharmacodynamics, secondary pharmacodynamics, safety pharmacology  studies, and pharmacodynamic drug interactions, which are subject to evaluation  during examination  of the preclinical  study results. The national guideline on evaluation of medicines does not contain any clear indication of the subject of examination in primary and secondary pharmacodynamic studies, which can make it difficult to prepare a registration dossier in the format of a Common Technical Document. The article formulates basic approaches to expert evaluation of the results of preclinical studies of primary and secondary pharmacodynamics of medicines. It determines the basics of expert evaluation which covers methodological framework of the research, results of the research, characteristics of the safety profile, extrapolation  of preclinical data, characteristics of risk factors and of the predictable clinical safety profile for patients.

1. Decision of the Council of the Eurasian Economic Commission, November 3, 2016, No. 78 «On rules of registration and evaluation of medicinal products for human use» (In Russ.)]

2. Engalycheva GN, Syubaev RD, Vasiliev AN, Snegireva AA, Verstakova OL. Preclinical safety pharmacology evaluation of medicinal products. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2013;(1):10–3 (In Russ.)

3. Engalycheva GN, Syubaev RD, Goryachev DV. Safety pharmacology studies of medicinal products: evaluation of results. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;7(2):92–7 (In Russ.)

4. Guidance on evaluation of medicines. V. I. Moscow: Grif i K; 2013 (In Russ.)

5. Melnikova EV, Merkulova OV, Chaplenko AA, Merkulov VA. Design of preclinical studies of biomedical cell products: characteristics, key principles and requirements. BIOpreparaty. Profilaktika, diagnostika, lechenie = BIOpreparations. Prevention, Diagnosis, Treatment. 2017;17(3):133–44 (In Russ.)

6. Guidance on preclinical studies of medicines. Part I. Moscow: Grif i K; 2012 (In Russ.)

7. Vogel HG, ed. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Berlin: Springer-Verlag; 2006.

8. Safety pharmacology studies for human pharmaceuticals (S7A) 2000. Available from: http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html

9. State Standard R 56700-2015. Medicines for medical applications. Safety pharmacology studies for human pharmaceuticals. Moscow: Standartinform; 2016 (In Russ.)

10. Valentin J-P, Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods. 2008;58(2):77–87. https://doi.org/10.1016/j.vascn.2008.05.007

11. Order of the Ministry of Health of the Russian Federation, August 24, 2017, No. 558n «On approval of the rules for the examination of medicinal products for medical use and the particular expertise of certain types of medicinal products for medical use (reference drugs) of medicinal products (biosimilars), homeopathic medicines, medicinal plants reparations, combinations of drugs), the forms of the conclusions of the commission of experts» (In Russ.)

12. World Health Organization. Quality practices in basic biomedical research. Training manual. 2010.

13. Ivanov SM. In silico assessment of the mechanisms of the side effects of drugs on the cardiovascular system. Cand. Biol. Sci. [thesis]. Moscow; 2014 (In Russ.)

14. Romanov BK, Alyautdin RN, Glagolev SV, Polivanov VA. Typical pharmacovigilance system master file (PSMF). Bezopasnost i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2016;(2):11–27 (In Russ.)